婴儿期癫痫快速基因组测序的可行性、诊断率与临床效用评估(Gene-STEPS):一项国际多中心先导队列研究
Gene-STEPS是一项国际多中心先导队列研究,纳入100例12月龄内起病的新发癫痫或复杂性热性惊厥婴儿,评估快速基因组测序的可行性、诊断率与临床效用。43例(43%,95%CI 33-53)获得遗传诊断,从癫痫起病到结果回报中位37天;遗传诊断与新生儿起病、重症监护转诊及自限性癫痫综合征相关,并影响治疗、额外评估、预后与复发风险咨询。
要点
- 100例婴儿中43例(43%,95%CI 33-53)通过快速基因组测序获得遗传诊断。
- 从癫痫起病到快速基因组测序结果回报中位37天(IQR 25-59)。
- 遗传诊断影响治疗24/43例(56%)、额外评估28/43例(65%)、预后37/43例(86%)及全部病例的复发风险咨询。
核心结论
- 研究结果支持在婴儿新发癫痫临床诊疗中实施快速基因组测序具有可行性。
- 需要纵向随访以进一步评估快速遗传诊断在改善临床、生活质量及经济结局方面的作用。
研究设计与样本
- 国际多中心先导队列研究(Gene-STEPS),为国际精准儿童健康伙伴关系(IPCHiP)的先导研究,IPCHiP由澳大利亚、加拿大、英国和美国的四个儿科中心组成。
- 纳入IPCHiP中心中癫痫起病年龄小于12月龄的新发癫痫或复杂性热性惊厥婴儿,排除单纯性热性惊厥、急性诱发性惊厥、已知获得性病因或已知遗传病因者。
- 采集先证者及可及生物学父母血样,父母均可用时行三人基因组测序,仅一方或无父母可用时行 duo 或单人基因组测序。
- 快速基因组测序与分析在临床认证实验室完成,结果返回家庭。
- 2021年9月1日至2022年8月31日共纳入100例婴儿,其中女孩41例(41%),男孩59例(59%)。
主要发现
- 100例婴儿中43例(43%[二项分布95%CI 33-53])获得遗传诊断,从癫痫起病到快速基因组测序结果回报中位37天(IQR 25-59)。
- 遗传诊断与新生儿起病相比婴儿期起病相关:新生儿起病14/19例(74%)vs 婴儿期起病29/81例(36%),p=0.0027。
- 遗传诊断与转诊场景相关:重症监护12/17例(71%)、非重症监护住院19/43例(44%)、门诊12/40例(28%),p=0.0178。
- 遗传诊断与癫痫综合征相关:自限性癫痫13/15例(87%)、发育性及癫痫性脑病18/51例(35%)、其他综合征12/34例(35%),p=0.001。
- 快速基因组测序揭示遗传异质性,涉及34个独特基因或基因组区域。
临床怎么用
- 作者认为研究结果支持在婴儿新发癫痫临床诊疗中实施快速基因组测序具有可行性。
- 作者指出需要纵向随访以进一步评估快速遗传诊断在改善临床、生活质量及经济结局方面的作用。
局限性
- 需要纵向随访以进一步评估快速遗传诊断在改善临床、生活质量及经济结局方面的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most neonatal and infantile-onset epilepsies have presumed genetic aetiologies, and early genetic diagnoses have the potential to inform clinical management and improve outcomes. We therefore aimed to determine the feasibility, diagnostic yield, and clinical utility of rapid genome sequencing in this population. METHODS: We conducted an international, multicentre, cohort study (Gene-STEPS), which is a pilot study of the International Precision Child Health Partnership (IPCHiP). IPCHiP is a consortium of four paediatric centres with tertiary-level subspecialty services in Australia, Canada, the UK, and the USA. We recruited infants with new-onset epilepsy or complex febrile seizures from IPCHiP centres, who were younger than 12 months at seizure onset. We excluded infants with simple febrile seizures, acute provoked seizures, known acquired cause, or known genetic cause. Blood samples were collected from probands and available biological parents. Clinical data were collected from medical records, treating clinicians, and parents. Trio genome sequencing was done when both parents were available, and duo or singleton genome sequencing was done when one or neither parent was available. Site-specific protocols were used for DNA extraction and library preparation. Rapid genome sequencing and analysis was done at clinically accredited laboratories, and results were returned to families. We analysed summary statistics for cohort demographic and clinical characteristics and the timing, diagnostic yield, and clinical impact of rapid genome sequencing. FINDINGS: Between Sept 1, 2021, and Aug 31, 2022, we enrolled 100 infants with new-onset epilepsy, of whom 41 (41%) were girls and 59 (59%) were boys. Median age of seizure onset was 128 days (IQR 46-192). For 43 (43% [binomial distribution 95% CI 33-53]) of 100 infants, we identified genetic diagnoses, with a median time from seizure onset to rapid genome sequencing result of 37 days (IQR 25-59). Genetic diagnosis was associated with neonatal seizure onset versus infantile seizure onset (14 [74%] of 19 vs 29 [36%] of 81; p=0·0027), referral setting (12 [71%] of 17 for intensive care, 19 [44%] of 43 non-intensive care inpatient, and 12 [28%] of 40 outpatient; p=0·0178), and epilepsy syndrome (13 [87%] of 15 for self-limited epilepsies, 18 [35%] of 51 for developmental and epileptic encephalopathies, 12 [35%] of 34 for other syndromes; p=0·001). Rapid genome sequencing revealed genetic heterogeneity, with 34 unique genes or genomic regions implicated. Genetic diagnoses had immediate clinical utility, informing treatment (24 [56%] of 43), additional evaluation (28 [65%]), prognosis (37 [86%]), and recurrence risk counselling (all cases). INTERPRETATION: Our findings support the feasibility of implementation of rapid genome sequencing in the clinical care of infants with new-onset epilepsy. Longitudinal follow-up is needed to further assess the role of rapid genetic diagnosis in improving clinical, quality-of-life, and economic outcomes. FUNDING: American Academy of Pediatrics, Boston Children's Hospital Children's Rare Disease Cohorts Initiative, Canadian Institutes of Health Research, Epilepsy Canada, Feiga Bresver Academic Foundation, Great Ormond Street Hospital Charity, Medical Research Council, Murdoch Children's Research Institute, National Institute of Child Health and Human Development, National Institute for Health and Care Research Great Ormond Street Hospital Biomedical Research Centre, One8 Foundation, Ontario Brain Institute, Robinson Family Initiative for Transformational Research, The Royal Children's Hospital Foundation, University of Toronto McLaughlin Centre.
引用
- D'Gama AM, Mulhern S, Sheidley BR, et al. Evaluation of the feasibility, diagnostic yield, and clinical utility of rapid genome sequencing in infantile epilepsy (Gene-STEPS): an international, multicentre, pilot cohort study. Lancet Neurol. 2023. PMID: 37596007. doi:10.1016/S1474-4422(23)00246-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。